These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39041287)

  • 1. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.
    Murer P; Brannetti B; Rondeau JM; Petersen L; Egli N; Popp S; Regnier C; Richter K; Katopodis A; Huber C
    MAbs; 2024; 16(1):2381891. PubMed ID: 39041287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
    Joerger M; Calvo E; Laubli H; Lopez J; Alonso G; Corral de la Fuente E; Hess D; König D; Sanchez Perez V; Bucher C; Jethwa S; Garralda E
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38243906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
    Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
    MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
    Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
    Mathiot L; Combarel D; Cagnat J; Delahousse J; Ouali K; Marabelle A; Loriot Y; Ponce S; Champiat S; Broutin S; Danlos FX
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
    Stringhini M; Mock J; Fontana V; Murer P; Neri D
    MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
    Wu J; Bloch N; Chang AY; Bhavsar R; Wang Q; Crawford A; DiLillo DJ; Vazzana K; Mohrs K; Dudgeon D; Patel S; Ahmed H; Garg V; Amatulli M; Antao OQ; Yan Y; Wang S; Ramos W; Krueger P; Adler C; Ni M; Wei Y; Guo C; Macdonald L; Huang T; Ullman E; Hermann A; Yancopoulos GD; Murphy AJ; Davis S; Olson WC; Lin JC; Smith E; Zhang T
    Cell Rep Med; 2024 Oct; 5(10):101747. PubMed ID: 39326410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.
    Sulzmaier FJ; Kern N; Ahn SJ; Polovina A; Ho J; Hussain A; Cyprus G; Macedo C; Pandit R; Crago W; Rowell E; Timmer JC; Eckelman BP
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.